Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: July 21, 2026
Reporting Period: Single event date (July 21, 2026)
Business Context: The Company is a Delaware corporation with principal executive offices in New York, NY. It is listed on The Nasdaq Stock Market LLC under the symbol "INBS".
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Regulation FD Disclosure (Item 7.01):
- The Company announced the completion of precision testing for its Intelligent Fingerprinting Drug Screening System.
- This testing is a key component of the Company's FDA 510(k) submission.
- The submission seeks U.S. market clearance for the detection of the opiate codeine.
Guidance, Outlook, and Risks
Management Commentary: The disclosure is qualified in its entirety by the full text of the Press Release furnished as Exhibit 99.1. The information is being furnished and is not deemed "filed" for purposes of the Securities Exchange Act of 1934, nor incorporated by reference unless specifically identified.
Risks and Contingencies: The filing does not explicitly detail risks or contingencies beyond the standard regulatory qualification that the press release information is not incorporated by reference.
Investor Verification Checklist
- Verify the full text of the Press Release (Exhibit 99.1) for detailed technical specifications of the precision testing.
- Confirm the status of the FDA 510(k) submission timeline and expected clearance dates.
- Review subsequent filings for any updates on the codeine detection system's market approval status.
- Check for any material changes in the Company's financial position resulting from this development in future periodic reports (10-Q or 10-K).